Payment overview · 2025
General Payments
$416.85
21 reported records · 11 companies
Healthcare provider profile · identity verified
John T Paulsel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1285611764
Verified facts
What the public records show
CMS Open Payments records show John T Paulsel, MD received $416.85 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $116.32 | 27.9% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $67.44 | 16.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.09 | 14.2% | 3 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.64 | 9.8% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $25.68 | 6.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $22.56 | 5.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.02 | 4.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.05 | 4.3% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.84 | 4.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.16 | 3.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.05 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $416.85 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $116.32 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $116.32 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.09 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.28 | 2 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
75 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 345 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 318 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 318 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 291 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 237 | 68 |
| Lisinopril | Lisinopril | 195 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 41 |
| Gabapentin | Gabapentin | 148 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 39 |
| Lorazepam | Lorazepam | 142 | 35 |
| Alprazolam | Alprazolam | 108 | 33 |
| Montelukast Sodium | Montelukast Sodium | 108 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 31 |
| Trazodone Hcl | Trazodone Hcl | 96 | 22 |
| Simvastatin | Simvastatin | 93 | 27 |
| Metformin Hcl | Metformin Hcl | 91 | 28 |
| Furosemide | Furosemide | 79 | 28 |
| Tramadol Hcl | Tramadol Hcl | 77 | 21 |
| Metformin Hcl Er | Metformin Hcl | 76 | 17 |
| Synthroid | Levothyroxine Sodium | 75 | 23 |
| Azithromycin | Azithromycin | 73 | 58 |
| Xarelto | Rivaroxaban | 73 | 15 |
| Sertraline Hcl | Sertraline Hcl | 71 | 20 |
| Omeprazole | Omeprazole | 70 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 19 |
| Ozempic | Semaglutide | 66 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 18 |
| Eliquis | Apixaban | 62 | 19 |
| Allopurinol | Allopurinol | 60 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | suppressed |
| Atenolol | Atenolol | 48 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 40 | 39 |
| Carvedilol | Carvedilol | 39 | 13 |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Prednisone | Prednisone | 39 | 27 |
| Diazepam | Diazepam | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Testosterone | Testosterone | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 25 |
| Finasteride | Finasteride | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | 11 |
| Glimepiride | Glimepiride | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | 11 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 14 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Xanax | Alprazolam | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $416.85 · 21 records | Novo Nordisk Inc | AIRSUPRA, ALVESCO, EDARBI, EVENITY, FARXIGA, ISTURISA, Kerendia, MOUNJARO, NEXLETOL, Ozempic, QULIPTA, Rybelsus, Tymlos, UNITHROID, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error